Dr. Michael E. Weinblatt, MD

Dr. Weinblatt practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Weinblatt's NPI, 1487768081, was assigned on August 19, 2006. Dr. Weinblatt graduated from University of Maryland School of Medicine in 1975. Dr. Weinblatt holds Massachusetts license 42413.

Dr. Weinblatt's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Weinblatt's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Weinblatt is also affiliated with Massachusetts General Hospital. The medical group on file is Brigham and Women's Hospital. Dmand AI also links Dr. Weinblatt to 3 more hospitals and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weinblatt practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Weinblatt's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Weinblatt is licensed in Massachusetts.

CMS data shows 631 Medicare services from Dr. Weinblatt across 4 procedure codes in 2024, for 329 Medicare patients. Medicare paid $42,252 for them.

CMS counts 329 Medicare patients who saw Dr. Weinblatt in 2024. The largest group is 65 to 74, with 151 patients. 75% of them have arthritis, and 71% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Weinblatt's median patient age at 72, with 68% women.

In 2024, Dr. Weinblatt wrote 2,197 Medicare Part D claims for 286 patients. 68% of them were for generic drugs. CMS names the drug for 2,010 of them, across 35 drugs with 11 or more claims each, at $4,527,798 in total drug cost. In 2023, CMS named 1,698 claims across 34 drugs.

Dr. Weinblatt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weinblatt as offering telehealth.

Dmand AI links 207 papers to Dr. Weinblatt, published from 2005 to 2025. 2019 was the busiest year, with 19. The most frequent topics are Arthritis, Rheumatoid, Antirheumatic Agents and Methotrexate. Dr. Weinblatt has published most often in Arthritis Rheumatol. Dr. Weinblatt's most frequent co-authors are Nancy Ann Shadick, MD, Mark Christopher Genovese, MD and Jeffrey A. Sparks, MD.

Dmand AI links Dr. Weinblatt to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Arthritis, Rheumatoid and Rheumatic Diseases. Open Payments lists research payments to Dr. Weinblatt that name 1 trial.

CMS Open Payments shows 401 general payments to Dr. Weinblatt from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Eli Lilly and Company paid the most, $121,197. It also lists 16 research payments totaling $10,941 from 2016 to 2020, naming 1 clinical trial.

Dr. Weinblatt graduated from University of Maryland School of Medicine in 1975.